Research Pipeline



With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.

Explore highlights of our research and development pipeline across our four areas of focus.

Items marked with ^ are being developed in collaboration with Regeneron, * are being developed in collaboration with Alnylam®, and ♦ are being developed in collaboration with Principia Biopharma Inc. Items shown with a † denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc.

Product Candidate Technology Phase I Phase II Phase III Current Phase

Immunology

Dupilumab^
Nasal Polyposis
mAb Dupilumab^ Nasal Polyposis - Phase I - 100% of progress Dupilumab^ Nasal Polyposis - Phase II - 100% of progress Dupilumab^ Nasal Polyposis - Phase III - 50% of progress PHASE III
Dupixent^
Atopic Dermatitis (12-17 years old)
mAb Dupixent Atopic Dermatitis (12-17 years old) - Phase I - 100% of progress Dupixent Atopic Dermatitis (12-17 years old) - Phase II - 100% of progress Dupixent Atopic Dermatitis (12-17 years old) - Phase III - 25% of progress PHASE III
Dupixent^
Atopic Dermatitis (6-11 years old)
mAb Dupixent Atopic Dermatitis (6-11 years old) - Phase I - 100% of progress Dupixent Atopic Dermatitis (6-11 years old) - Phase II - 100% of progress Dupixent Atopic Dermatitis (6-11 years old) - Phase III - 25% of progress PHASE III
Dupixent^
Atopic Dermatitis (6 mo - 5 years old)
mAb Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase I - 100% of progress Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase II - 100% of progress Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase III - 25% of progress PHASE III
Dupixent^
Asthma (6-11 years old)
mAb Dupilumab^ Asthma - Phase I - 100% of progress Dupilumab^ Asthma - Phase II - 100% of progress Dupilumab^ Asthma - Phase III - 25% of progress PHASE II
Dupilumab^
Eosinophilic Esophagitis
mAb Dupilumab^ Eosinophilic esophagitis - Phase I - 100% of progress Dupilumab^ Eosinophilic esophagitis - Phase II - 100% of progress Dupilumab^ Eosinophilic esophagitis - Phase III - 25% of progress PHASE II
Dupilumab^
Grass Immunotherapy
mAb Dupilumab^ Grass Immunotherapy - Phase I - 100% of progress Dupilumab^ Grass Immunotherapy - Phase II - 100% of progress Dupilumab^ Grass Immunotherapy- Phase III - 25% of progress PHASE II
Dupilumab^ + AR101-CODIT
Peanut Allergy - Pediatric
mAb Dupilumab^ +AR101-CODIT - Phase I - 100% of progress Dupilumab^ +AR101-CODIT - Phase II - 100% of progress Dupilumab^ +AR101-CODIT- Phase III - 25% of progress PHASE II
Sarilumab^
Giant Cell Arteritis
mAb Sarilumab^  Giant Cell Arteritis - Phase I - 100% of progress Sarilumab^  Giant Cell Arteritis - Phase II - 100% of progress Sarilumab^  Giant Cell Arteritis - Phase III - 25% of progress PHASE III
Sarilumab^
Polymyalgia Rheumatica
mAb Sarilumab^ Polymyalgia Rheumatica - Phase I - 100% of progress Sarilumab^ Polymyalgia Rheumatica - Phase II - 100% of progress Sarilumab^ Polymyalgia Rheumatica - Phase III - 25% of progress PHASE III
SAR440340^
Asthma
mAb SAR440340 Asthma - Phase I - 100% of progress SAR440340 Asthma - Phase II - 25% of progress SAR440340 Asthma - Phase III - 0% of progress PHASE II
SAR440340^
COPD
mAb SAR440340 COPD - Phase I - 100% of progress SAR440340 COPD - Phase II - 25% of progress SAR440340 COPD - Phase III - 0% of progress PHASE II
Sarilumab^
Polyarticular Juvenile Idiopathic Arthritis
mAb Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase I - 100% of progress Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase II - 25% of progress Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase III - 0% of progress PHASE II
Sarilumab^
Systemic Juvenile Arthritis
mAb Sarilumab Systemic Juvenile Arthritis - Phase I - 100% of progress Sarilumab Systemic Juvenile Arthritis - Phase II - 25% of progress Sarilumab Systemic Juvenile Arthritis - Phase III - 0% of progress PHASE II
SAR156579^
Systemic Scleroderma
mAb Systemic Scleroderma - Phase I - 100% of progress SSystemic Scleroderma - Phase II - 25% of progress Systemic Scleroderma - Phase III - 0% of progress PHASE II
SAR439794^
Peanut Allergy
mAb SAR439794 Peanut Allergy - Phase I - 50% of progress SAR439794 Peanut Allergy - Phase II - 0% of progress SAR439794 Peanut Allergy - Phase III - 0% of progress PHASE I

Oncology

Isatuximab
Relapsing Refractory Multiple Myeloma (IKEMA)
mAb Isatuximab Relapsing Refractory Multiple Myeloma - Phase I - 100% of progress Isatuximab Relapsing Refractory Multiple Myeloma - Phase II - 100% of progress Isatuximab Relapsing Refractory Multiple Myeloma - Phase III - 50% of progress PHASE III
Isatuximab
Newly Diagnosed Multiple Myeloma
mAb Isatuximab Newly Diagnosed MM - Phase I - 100% of progress Isatuximab Newly Diagnosed MM - Phase II - 100% of progress Isatuximab Newly Diagnosed MM - Phase III - 25% of progress PHASE III
Isatuximab
1L Newly Diagnosed Multiple Myeloma (IMROZ)
mAb Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase I - 100% of progress Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase II - 100% of progress Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase III - 25% of progress PHASE III
Cemiplimab^▼
1L Non-small Cell Lung Cancer
mAb Cemiplimab^ Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^ Non-small Cell Lung Cancer - Phase II - 100% of progress Cemiplimab^ Non-small Cell Lung Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^▼
2L Cervical Cancer
mAb Cemiplimab^  2L Cervical Cancer - Phase I - 100% of progress Cemiplimab^  2L Cervical Cancer - Phase II - 100% of progress Cemiplimab^  2L Cervical Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^▼ + Ipilimumab
1L Non-small Cell Lung Cancer
mAb Cemiplimab^▼ + ipilimumab  1L Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^▼ + ipilimumab  1L Non-small Cell Lung Cancer - Phase II - 100% of progress Cemiplimab^▼ + ipilimumab  1L Non-small Cell Lung Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^▼
Advanced BCC
mAb Cemiplimab^ Advanced BCC - Phase I - 100% of progress Cemiplimab^ Advanced BCC - Phase II - 50% of progress Cemiplimab^ Advanced BCC - Phase III - 0% of progress PHASE II
 Cemiplimab^
2L Non-small Cell Lung Cancer
mAb  Cemiplimab^ 2L Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^ 2L Non-small Cell Lung Cancer - Phase II - 50% of progress Cemiplimab^ 2L Non-small Cell Lung Cancer - Phase III - 0% of progress PHASE II 
 Isatuximab + Cemiplimab^
Relapsing Refractory Multiple Myeloma
mAb  isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase I - 100% of progress isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase II - 50% of progress isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase III - 0% of progress PHASE II 
 Isatuximab + Cemiplimab^
Advanced Malignancies
mAb  isatuximab + Cemiplimab^ Advanced Malignancies - Phase I - 100% of progress isatuximab + Cemiplimab^ Advanced Malignancies - Phase II - 50% of progress isatuximab + Cemiplimab^ Advanced Malignancies - Phase III - 0% of progress PHASE II 
 Isatuximab + atezolizumab
Advanced Malignancies
mAb  isatuximab + atezolizumab^ Advanced Malignancies - Phase I - 100% of progress isatuximab + atezolizumab^ Advanced Malignancies - Phase II - 50% of progress isatuximab + atezolizumab^ Advanced Malignancies - Phase III - 0% of progress PHASE II 
SAR439459 (TGFβ)
Advanced Solid Tumors 
mAb SAR439459 Advanced Solid Tumors - Phase I - 50% of progress SAR439459 Advanced Solid Tumors - Phase II - 0% of progress SAR439459 Advanced Solid Tumors - Phase III - 0% of progress PHASE I
SAR408701 (CEACAM5)
Solid tumors
mAb SAR408701 Solid tumors - Phase I - 50% of progress SAR408701 Solid tumors - Phase II - 0% of progress SAR408701 Solid tumors - Phase III - 0% of progress PHASE I

Rare Diseases

Fitusiran*
Hemophilia A & B
RNAi Fitusiran* Hemophilia A & B - Phase I - 100% of progress Fitusiran* Hemophilia A & B - Phase II - 100% of progress Fitusiran* Hemophilia A & B - Phase III - 50% of progress PHASE III
Avalglucosidase alfa
Pompe disease, 2nd generation enzyme
protein-based therapy Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase I - 100% of progress Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase II - 100% of progress Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase III - 25% of progress PHASE III
Venglustat
Autosomal Dominant Polycystic Kidney Disease
small molecule Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase I - 100% of progress Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase II - 100% of progress Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase III - 25% of progress PHASE III
Eliglustat
Gaucher Type 1, switch from ERT - Pediatric
small molecule Eliglustat - Phase I - 100% of progress Eliglustat  - Phase II - 100% of progress Eliglustat  - Phase III - 25% of progress PHASE III
Olipudase Alfa†
Acid Sphingomyelinase Deficiency (ASMD)
protein-based therapy Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase I - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase II - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase III - 0% of progress PHASE II
Venglustat
Fabry disease
small molecule venglustat Fabry disease - Phase I - 100% of progress venglustat Fabry disease - Phase II - 100% of progress venglustat Fabry disease - Phase III - 0% of progress PHASE II
SAR339375
Alport Syndrome
RNAi venglustat Parkinson's disease with a GBA mutation - Phase I - 100% of progress venglustat Parkinson's disease with a GBA mutation - Phase II - 25% of progress venglustat Parkinson's disease with a GBA mutation - Phase III - 0% of progress PHASE II
Venglustat
Parkinson's disease with a GBA mutation
small molecule venglustat Parkinson's disease with a GBA mutation - Phase I - 100% of progress venglustat Parkinson's disease with a GBA mutation - Phase II - 25% of progress venglustat Parkinson's disease with a GBA mutation - Phase III - 0% of progress PHASE II
Venglustat
Gaucher Type 3
small molecule venglustat Gaucher Type 3 - Phase I - 100% of progress venglustat Gaucher Type 3 - Phase II - 25% of progress venglustat Gaucher Type 3 - Phase III - 0% of progress PHASE II

Multiple Sclerosis

SAR442168♦
Multiple Sclerosis
BTK inhibitor GLD52 (GZ402668) Multiple Sclerosis - Phase I - 50% of progress GLD52 (GZ402668) Multiple Sclerosis - Phase II - 0% of progress GLD52 (GZ402668) Solid tumors - Phase III - 0% of progress PHASE I

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remylination.

Scientist in lab

Avalglucosidase alfa clinical trial

Learn more about the ongoing phase 3 clinical trial for avalglucosidase alfa, an investigational enzyme replacement therapy being studied for the treatment of Pompe disease.
Scientist at microscope

Sanofi’s R&D portfolio

The full Sanofi research pipeline focuses on finding innovative solutions to a variety of major public health challenges.